← All trials
NCT01337167
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2011
- Primary completion
- May 1, 2013
- Completion date
- May 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 1473
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- MerckLead sponsor
- Sanofi-AventisCollaborator
- MerckStudy director
Drugs studied
- haemophilus influenzae type b-neisseria meningitidis serogroups c and y-tetanus-toxoid conjugate vaccine
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- pneumococcal 13-valent conjugate vaccine
- pneumococcal 13-valent conjugate vaccine
- hepatitis b vaccine (recombinant)
- rotavirus vaccine, live, oral, pentavalent
- rotavirus vaccine, live, oral, pentavalent
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- measles, mumps, and rubella vaccine
- haemophilus influenzae type b conjugate vaccine
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.